Leucovorin
- Generic Name
- Leucovorin
- Brand Names
- EnBrace HR, EnLyte, Lederle Leucovorin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23N7O7
- CAS Number
- 58-05-9
- Unique Ingredient Identifier
- Q573I9DVLP
- Background
Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...
- Indication
For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...
- Associated Conditions
- Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
- Associated Therapies
- -
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 22
- Registration Number
- NCT00450801
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery
- First Posted Date
- 2007-03-19
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 29
- Registration Number
- NCT00448760
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-03-19
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 25
- Registration Number
- NCT00448682
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-03-19
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 25
- Registration Number
- NCT00449163
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Combination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric Patients
- Conditions
- Interventions
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2009-09-28
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 110
- Registration Number
- NCT00447967
- Locations
- 🇬🇷
State General Hospital of Larissa, Larissa, Greece
🇬🇷"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
🇬🇷University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
- Conditions
- Interventions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2014-03-14
- Lead Sponsor
- PD Dr. med. Volker Heinemann
- Target Recruit Count
- 568
- Registration Number
- NCT00433927
- Locations
- 🇩🇪
University of Munich - Klinikum Grosshadern, Munich, Germany
A Single Arm Trial of Oxaliplatin and 5FU With Concurrent Radiation in Patients With Metastatic Rectal Cancer
- Conditions
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2011-12-15
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 26
- Registration Number
- NCT00422864
- Locations
- 🇦🇺
Peter MacCaluum Cancer Centre, Melbourne, Victoria, Australia
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 266
- Registration Number
- NCT00418938
Vitamins and Minerals for Children With Downs Syndrome
- Conditions
- First Posted Date
- 2006-09-20
- Last Posted Date
- 2006-09-20
- Lead Sponsor
- Institute of Child Health
- Registration Number
- NCT00378456
- Locations
- 🇬🇧
Institute of Child Health, London, London, United Kingdom
🇬🇧Peninsular Medical School, Exeter, United Kingdom
🇬🇧Institute of Child Health, Birmingham, United Kingdom
Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2011-10-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT00354978
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Lyndon Baines Johnson General Hospital, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.